Evidence map›Paper›PMID 42277205›Full record

ArticleActa pharmacologica Sinica2026

S1UTRSP5, a short restructured RNA from SLIT1 3'UTR, mitigates mouse cardiac remodeling via enhancing SlRT1 activity.

Jin-Feng Su, Tao Ou, Xiao-Yao Liu, Xue-Min Su, Ya Wang, Yi-Hong Wen, Yuan Gao, Ruo-Han Li, Lu-Fang Huang, Chuan-Meng Zhou and 9 more

Abstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jin-Feng Su *School of Medicine, South China University of Technology, Guangzhou, 510006, China.
Tao Ou *Key Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Xiao-Yao Liu *School of Basic Medical Sciences, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou, 510005, China.
Xue-Min Su *School of Medicine, South China University of Technology, Guangzhou, 510006, China.
Ya WangSchool of Medicine, South China University of Technology, Guangzhou, 510006, China.
Yi-Hong WenKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Yuan GaoSchool of Medicine, South China University of Technology, Guangzhou, 510006, China.
Ruo-Han LiSchool of Medicine, South China University of Technology, Guangzhou, 510006, China.
Lu-Fang HuangKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Chuan-Meng ZhouKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Heng-Li ZhaoKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Jie-Ning ZhuKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Ning MaSchool of Basic Medical Sciences, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou, 510005, China.
Xi-Long ZhengDepartment of Biochemistry & Molecular Biology, Libin Cardiovascular Institute, The University of Calgary, Calgary, AB, Canada.
Yu-Peng LiuGuangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Jin-Dong XuKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Hui LiKey Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China. lihui3205@gdph.org.cn.
Xian-Hong FangGuangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China. fangxianhong@gdph.org.cn.
Zhi-Xin ShanSchool of Medicine, South China University of Technology, Guangzhou, 510006, China. shanzhixin@gdph.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 3' untranslated regions (3'UTRs) have been known to regulate mRNA location, stability, and translation. 3'UTR length regulation is involved in the pathogenesis of cardiac dysfunction; however, more about the roles of 3'UTRs in cardiac remodeling remains elusive. In this study, we found slit guidance ligand 1 (SLIT1) 3'UTR with 3074 nt in length, which was 10-fold higher than SLIT1 coding sequence (CDS), was significantly decreased in the myocardium of patients with heart failure (HF) (n = 40) in comparison with healthy organ donors (n=17). We revealed that SLIT1 3'UTR and the 1526 nt fragment of SLIT1 3'UTR (FS1UTR) mainly and specifically combined miR-34a-5p, and improved cardiac remodeling through the miR-34a-5p/SIRT1 axis independently of Slit1 expression. Furthermore, a 260 nt restructured RNA derived from FS1UTR, S1UTRSP5, which contains 5 binding sites of miR-34a-5p seed sequence, alleviated cardiac remodeling in vitro and in vivo. We demonstrated that S1UTRSP5 blocked the function of miR-34a-5p and activated the SIRT1-PGC-1α-Nrf2 axis in cardiomyocytes, and promoted the SIRT1/Smad3 signal in cardiac fibroblasts and the SIRT1-eNOS-VEGFA axis in endothelial cells, collectively contributing to the amelioration of cardiac remodeling. These results provide new insights into the development of S1UTRSP5 as a novel inhibitor of miR-34a-5p for cardiac remodeling and HF. The human SLIT1 3'UTR or FS1UTR combines miR-34a-5p to increase SIRT1 level in CMs, CFs and ECs. Notably, S1UTRSP5, a 260-nt stable RNA derived from SLIT1 3'UTR, efficiently sponged miR-34a-5p to activate SIRT1-PGC-1α-Nrf2 pathway in CMs, and to promote SIRT1/Smad3 signal in CFs and the SIRT1-eNOS-VEGFA pathway in ECs, collectively contributing to amelioration of cardiac remodeling.

Indexed as

3' Untranslated RegionsHeart FailureNerve Tissue ProteinsVentricular RemodelingAnimalsFemaleHumansMaleMiceMice, Inbred C57BLMicroRNAsMyocytes, CardiacSirtuin 13' Untranslated RegionsMicroRNAsMIRN34 microRNA, humanNerve Tissue ProteinsSirtuin 13′ untranslated regioncardiac remodelinghuman cardiac organoidmicroRNAsSIRT1

Identifiers

PMID42277205
PMCPMC13486678

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.